Saul Priceman, Ph.D.
Saul Priceman, Ph.D., is an associate professor and associate director of Translational Sciences & Technologies in the T Cell Therapeutics Research Laboratories at City of Hope, as well as a trained tumor immunologist with expertise in T cell biology and cancer immunotherapy. He is developing chimeric antigen receptor (CAR)-based T cell immunotherapy primarily for solid cancers, with a strong focus on metastatic disease in breast, prostate and pancreatic cancer.
Dr. Priceman received his B.S. in microbiology at University of California Santa Barbara, and his Ph.D. in molecular and medical pharmacology at University of California Los Angeles.
Dr. Priceman is a principal investigator on multiple grants including from the National Institute of Health (NIH), Department of Defense, California Institute for Regenerative Medicine, Prostate Cancer Foundation, and the National Comprehensive Cancer Network, leading the development of solid tumor CAR T cell therapies and working with his team optimizing new immunotherapy strategies to target tumor immunosuppression.
Dr. Priceman is deeply committed to rapidly advancing potentially paradigm-shifting immunotherapy on behalf of patients with cancer, in part because of personal experiences with family and friends who have struggled with the disease. His overarching goal is to develop a range of effective immunotherapies for solid cancers, based on the powerful CAR T cell platform, with the knowledge that any single therapy will not likely provide durable responses in advanced disease.
Duarte Cancer Center
Duarte, CA 91010
-
2023-present, Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation, Comprehensive Cancer Center, City of Hope, Duarte, CA
- 2018-2023, Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, Comprehensive Cancer Center, City of Hope, Duarte, CA
-
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Bhatia V, Kamat NV, Pariva TE, Wu LT, Tsao A, Sasaki K, Sun H, Javier G, Nutt S, Coleman I, Hitchcock L, Zhang A, Rudoy D, Gulati R, Patel RA, Roudier MP, True LD, Srivastava S, Morrissey CM, Haffner MC, Nelson PS, Priceman SJ, Ishihara J, Lee JK.Nat Commun. 2023 Apr 11;14(1):2041. doi: 10.1038/s41467-023-37874-2.PMID: 37041154.
-
Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases. Yang A, Zhang Z, Chaurasiya S, Park AK, Jung A, Lu J, Kim SI, Priceman S, Fong Y, Woo Y.J Immunother Cancer. 2023 Apr;11(4):e006280. doi: 10.1136/jitc-2022-006280.PMID: 37019471.
-
Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting. Jun Lee EH, Cullen C, Murad JP, Gumber D, Park AK, Yang J, Stern LA, Adkins LN, Dhapola G, Gittins B, Chung-Chang W, Martinez C, Woo Y, Cristea M, Rodriguez-Rodriguez L, Ishihara J, Lee JK, Forman SJ, Wang LD, Priceman SJ.bioRxiv. 2023 Jan 7:2023.01.06.522784. doi: 10.1101/2023.01.06.522784. Preprint.PMID: 36711615.
-
PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages. Yamaguchi Y, Gibson J, Ou K, Lopez LS, Ng RH, Leggett N, Jonsson VD, Zarif JC, Lee PP, Wang X, Martinez C, Dorff TB, Forman SJ, Priceman SJ.J Immunother Cancer. 2022 Jun;10(6):e004400. doi: 10.1136/jitc-2021-004400.PMID: 35738799.
-
Advancing together and moving forward: Combination gene and cellular immunotherapies. Priceman SJ, Cheema W, Adusumilli PS.Mol Ther Oncolytics. 2022 May 30;25:330-334. doi: 10.1016/j.omto.2022.05.005. eCollection 2022 Jun 16.PMID: 35694448.
-
Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer. Dellinger TH, Han ES, Raoof M, Lee B, Wu X, Cho H, He TF, Lee P, Razavi M, Liang WS, Schmolze D, Priceman SJ, Lee S, Lin WC, Lin JF, Kebria M, Hakim A, Ruel N, Stewart DB, Wang EW, Paz BI, Wakabayashi MT, Cristea MC, Rodriguez-Rodriguez L.JCO Precis Oncol. 2022 Mar;6:e2100239. doi: 10.1200/PO.21.00239.PMID: 35357903. Clinical Trial.
-
Off-the-Shelf Prostate Stem Cell Antigen-Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer. Teng KY, Mansour AG, Zhu Z, Li Z, Tian L, Ma S, Xu B, Lu T, Chen H, Hou D, Zhang J, Priceman SJ, Caligiuri MA, Yu J.Gastroenterology. 2022 Apr;162(4):1319-1333. doi: 10.1053/j.gastro.2021.12.281. Epub 2022 Jan 6.PMID: 34999097.
-
Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer. Dorff TB, Narayan V, Forman SJ, Zang PD, Fraietta JA, June CH, Haas NB, Priceman SJ.Clin Cancer Res. 2022 Feb 15;28(4):576-584. doi: 10.1158/1078-0432.CCR-21-1483.PMID: 34675084.
-
Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control. Miller IC, Zamat A, Sun LK, Phuengkham H, Harris AM, Gamboa L, Yang J, Murad JP, Priceman SJ, Kwong GA.Nat Biomed Eng. 2021 Nov;5(11):1348-1359. doi: 10.1038/s41551-021-00781-2. Epub 2021 Aug 12.PMID: 34385695.
-
Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Murad JP, Tilakawardane D, Park AK, Lopez LS, Young CA, Gibson J, Yamaguchi Y, Lee HJ, Kennewick KT, Gittins BJ, Chang WC, Tran CP, Martinez C, Wu AM, Reiter RE, Dorff TB, Forman SJ, Priceman SJ.Mol Ther. 2021 Jul 7;29(7):2335-2349. doi: 10.1016/j.ymthe.2021.02.024. Epub 2021 Feb 27.PMID: 33647456.